Evidence map›Paper›PMID 27296847›Full record

ArticleThe Journal of infectious diseases2016

Monitoring for Human Papillomavirus Vaccine Impact Among Gay, Bisexual, and Other Men Who Have Sex With Men-United States, 2012-2014.

Elissa Meites, Pamina M Gorbach, Beau Gratzer, Gitika Panicker, Martin Steinau, Tom Collins, Adam Parrish, Cody Randel, Mark McGrath, Steven Carrasco and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Prevalence and Risk Factors of Human Papillomavirus in Male Patients: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2018
    Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

Elissa MeitesDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases.
Pamina M GorbachDepartment of Epidemiology, Fielding School of Public Health, University of California-Los Angeles.
Beau GratzerHoward Brown Health, Chicago, Illinois.
Gitika PanickerDivision of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases.
Martin SteinauDivision of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases.
Tom CollinsCollege of Public Health, University of Kentucky, Lexington.
Adam ParrishCollege of Public Health, University of Kentucky, Lexington.
Cody RandelHoward Brown Health, Chicago, Illinois.
Mark McGrathDepartment of Epidemiology, Fielding School of Public Health, University of California-Los Angeles.
Steven CarrascoDepartment of Epidemiology, Fielding School of Public Health, University of California-Los Angeles.
Janell MooreDepartment of Epidemiology, Fielding School of Public Health, University of California-Los Angeles.
Akbar ZaidiDivision of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
Jim BraxtonDivision of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
Peter R KerndtDepartment of Epidemiology, Fielding School of Public Health, University of California-Los Angeles.
Elizabeth R UngerDivision of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases.
Richard A CrosbyCollege of Public Health, University of Kentucky, Lexington.
Lauri E MarkowitzDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases.
University of California, Los Angeles · USNational Center for Emerging and Zoonotic Infectious Diseases · USUniversity of Kentucky · USHoward Brown Health Center · USNational Center for Immunization and Respiratory Diseases · USCenters for Disease Control and Prevention · USNational Center for HIV/AIDS Viral Hepatitis STD and TB Prevention · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundGay, bisexual, and other men who have sex with men (MSM) are at high risk for human papillomavirus (HPV) infection; vaccination is recommended for US males, including MSM through age 26 years. We assessed evidence of HPV among vaccine-eligible MSM and transgender women to monitor vaccine impact.

methodsDuring 2012-2014, MSM aged 18-26 years at select clinics completed a computer-assisted self-interview regarding sexual behavior, human immunodeficiency virus (HIV) status, and vaccinations. Self-collected anal swab and oral rinse specimens were tested for HPV DNA (37 types) by L1 consensus polymerase chain reaction; serum was tested for HPV antibodies (4 types) by a multiplexed virus-like particle-based immunoglobulin G direct enzyme-linked immunosorbent assay.

resultsAmong 922 vaccine-eligible participants, the mean age was 23 years, and the mean number of lifetime sex partners was 37. Among 834 without HIV infection, any anal HPV was detected in 69.4% and any oral HPV in 8.4%, yet only 8.5% had evidence of exposure to all quadrivalent vaccine types. In multivariate analysis, HPV prevalence varied significantly (P < .05) by HIV status, sexual orientation, and lifetime number of sex partners, but not by race/ethnicity. DISCUSSIONS: Most young MSM lacked evidence of current or past infection with all vaccine-type HPV types, suggesting that they could benefit from vaccination. The impact of vaccination among MSM may be assessed by monitoring HPV prevalence, including in self-collected specimens.

Indexed as

Sexual and Gender MinoritiesAdolescentAdultAnal CanalAntibodies, ViralCross-Sectional StudiesEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMouth MucosaPapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesPolymerase Chain ReactionSexual BehaviorAntibodies, ViralPapillomavirus Vaccinesepidemiological monitoringhomosexuality, malepapillomavirus infectionspapillomavirus vaccines

Identifiers

PMID27296847
PMCPMC5049501
OpenAlexW2475963208

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.